Last reviewed · How we verify
NCT05181059: DECREAS
DLSCT for Breast Cancer Detection in Women With Dense Breasts
trial testing Dual-layer spectral computerized tomography (DLSCT) in Breast Neoplasms in 14 participants. Status unknown.
1 January 2023
Quick facts
| Lead sponsor | Rijnstate Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 14 |
| Start date | 1 January 2022 |
| Primary completion | 1 January 2023 |
| Estimated completion | 1 January 2023 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Dual-layer spectral computerized tomography (DLSCT)
Conditions studied
- Breast Neoplasms — all drugs for Breast Neoplasms →
- Breast Density — all drugs for Breast Density →
- Radiographic Image Interpretation, Computer-Assisted — all drugs for Radiographic Image Interpretation, Computer-Assisted →
Sponsor
Rijnstate Hospital
Who can join
18 and older, female only, with Breast Neoplasms or Breast Density. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this project is to demonstrate the feasibility of DLSCT to detect breast cancer in women with dense breasts. Patients with locoregional advanced primary breast cancer and heterogeneously (n = 7) or extremely dense breasts (n = 7) as determined by mammography will be included in this study. These patients have an indication for a positron emission tomography computed tomography (PET-CT) scan to search for distant metastases. In this study the participants will undergo an additional contrast enhanced DLSCT scan to determine the feasibility of spectral CT to detect breast cancer in women with dense breasts.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05181059
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Neoplasms
Currently open trials in the same condition.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
- NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
- NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
- NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting
Other Rijnstate Hospital trials
Trials by the same sponsor.
- NCT07070583 — Impact of Aorto-Iliac Occlusive Disease Treatment on Blood Pressure · NA · recruiting
- NCT07304401 — Evaluation of Effectiveness of Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy for Treatment of Chemotherapy Induce · recruiting
- NCT06883591 — Triaxial Accelerometry Study · active not recruiting
- NCT06827509 — Blood Flow Evaluation After Carotid Surgical Treatment · not yet recruiting
- NCT05633550 — Flexion-Extension Radiograph Imaging Protocol Reliability Study · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05181059 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rijnstate Hospital
- Last refreshed: 6 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05181059.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing